摘要
目的研究HP方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副作用。方法38例晚期非小细胞肺癌患者应用HCPT10mg/m2/d,静脉滴注,第1天至第5天;DDP20mg/m2/d,静脉滴注,第1天至第5天;21d为1个周期,连用3个周期。结果38例CR13.2%(5/38),PR39.5%(15/38),SD36.8%(14/38),PD10.5%(4/38),总有效率52.6%(20/38)。结论HCPT联合DDP的HP方案治疗晚期NSCLC为较有效方案,毒性低,值得临床推广研究。
Objective To Observe the clinical curative effects and toxical effects of advanced non-small cell lung cancer （NSCLC） patients treated with HCPT and DDP. Methods This clinical study was designed to treat 38 patients with NSCLC. Infusion of HCPT 10mg/mg/d lasted 5 days, and ifusion of DDP20 mg/m^2/day lasted 5 days, every 21 days was a cycle,which was used for 3 cycles. Results Gross efficiency rate was 52.6% with CR 13.2% （5/38）, PR 39. 5% （ 15/38 ）, SD 36. 8% （ 14/38 ）and PD 10. 5% （4/ 38 ）. Conclusion The HP regimen had good curative and less toxical effects. It is worthy of further research and expansion in clinical practice.
出处
《临床肺科杂志》
2007年第6期543-544,共2页
Journal of Clinical Pulmonary Medicine
关键词
羟基喜树碱
顺铂
非小细胞肺癌
化疗
Hydrxy camptothecine
cisplatin
Non-small cell lung cancer
chemical treatment
